Syndax Pharmaceuticals (SNDX) PT Raised to $27 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts SNDX Hot Sheet
Price: $14.29 --0%
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Baird analyst Madhu Kumar raised the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $27.00 (from $20.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Syndax Pharmaceuticals (SNDX) PT Lowered to $36 at H.C. Wainwright
- Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
- Graphic Packaging Holding Company (GPK) PT Raised to $12 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
